Literature DB >> 8239620

Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

R S Witzig1, S G Franzblau.   

Abstract

The MICs of ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid for clinical isolates of Mycobacterium kansasii were determined by the radiometric (BACTEC) method. All drugs except azithromycin elicited MICs for 90% of the strains tested that were lower than previously reported achievable maximum concentrations in serum. Ofloxacin, sparfloxacin, and clarithromycin had the largest maximum concentration in serum/MIC for 90% of strains ratio of the drugs tested.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8239620      PMCID： PMC188108          DOI： 10.1128/AAC.37.9.1997

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  The site concentrations of antimicrobial agents in the lung.

Authors:  D Honeybourne; D R Baldwin
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

2.  In vitro susceptibility of Mycobacterium kansasii to clarithromycin.

Authors:  J Biehle; S J Cavalieri
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

4.  Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii.

Authors:  G D Harris; W G Johanson; D P Nicholson
Journal:  Am Rev Respir Dis       Date:  1975-07

5.  Susceptibility of strains of the Mycobacterium tuberculosis complex to fusidic acid.

Authors:  K Fuursted; D Askgaard; V Faber
Journal:  APMIS       Date:  1992-07       Impact factor: 3.205

6.  Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.

Authors:  D Van Caekenberghe
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

7.  The course of untreated Mycobacterium kansasii disease.

Authors:  P B Francis; S J Jay; W G Johanson
Journal:  Am Rev Respir Dis       Date:  1975-04

8.  Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice.

Authors:  S G Franzblau; M L Parrilla; G P Chan
Journal:  Int J Lepr Other Mycobact Dis       Date:  1993-03

9.  Evaluation of new anti-infective drugs for the treatment of disease caused by Mycobacterium kansasii and other mycobacteria. Infectious Diseases Society of America and the Food and Drug Administration.

Authors:  P Hopewell; M Cynamon; J Starke; M Iseman; R O'Brien
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

10.  Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

Authors:  S Y Chu; L T Sennello; S T Bunnell; L L Varga; D S Wilson; R C Sonders
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191
View more
  3 in total

1.  Skin lesions in a patient with hairy cell leukaemia.

Authors:  P Raanani; M Thaler; N Keller; I Ben-Bassat
Journal:  Postgrad Med J       Date:  1997-06       Impact factor: 2.401

2.  Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albumin.

Authors:  Godwin Akpeko Dziwornu; Stephanie Kamunya; Tando Ntsabo; Kelly Chibale
Journal:  Medchemcomm       Date:  2019-04-18       Impact factor: 3.597

3.  Therapy for Mycobacterium kansasii Infection: Beyond 2018.

Authors:  Michelle S DeStefano; Carolyn M Shoen; Michael H Cynamon
Journal:  Front Microbiol       Date:  2018-09-24       Impact factor: 5.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.